Latest Nicholas J. Vogelzang Stories

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated...

ACF Welcomes Prominent Veterinary and Human Oncologists to its Scientific Advisory Council. The Council Advises the Executive Board on Comparative Oncology Award Grant Criteria and Evaluation. Norwalk, Connecticut (PRWEB) April 10, 2013 Animal Cancer Foundation (ACF) has appointed several prominent leaders in the veterinary and human oncology field to serve as Scientific Advisory Council to its Executive Board. (http://www.acfoundation.org/about/council.php) The Scientific Advisory...

Despite menopause-like side effects, continuous hormone treatment is superior to intermittent therapy A study published today in the New England Journal of Medicine recommends a dramatic shift in the way doctors treat metastatic prostate cancer. "These results have changed the way I treat patients," said Ian M. Thompson Jr., M.D., director of the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and senior author on the international...

WAYNE, N.J., Feb. 13, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "We are pleased the FDA has granted priority review...

ORLANDO, Fla., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC [Janssen] announced today updated results showing ZYTIGA(®) (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer. The Phase 3, randomized, multicenter, placebo-controlled study (COU-AA-302) also demonstrated...

Digital Science Press, Inc. announces UroToday.com is expanding editorial content with more indepth clinical education for the urologists and medical oncologists on immunotherapy treatments for men with metastatic castration-resistant prostate cancer (mCRPC). UroToday publishes two year-end review white papers: Best of Prostate and the Best of mCRPC featuring interviews with prostate cancer experts. Berkeley, CA (PRWEB) December 19, 2012 Now in its tenth year as an online urology-medical...

RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC announced today that results from analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study of ZYTIGA(® )(abiraterone acetate) plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to chemotherapy, have been published online in The New England Journal of Medicine. This study was the basis of Monday's U.S. Food and Drug Administration (FDA)...

HORSHAM, Pa., Dec. 10, 2012 /PRNewswire/ -- Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA(®) (abiraterone acetate). Until now, ZYTIGA with prednisone has only been approved to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. With this approval, ZYTIGA, in combination with prednisone, may now be used...

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 6, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the completion of patient enrollment in the primary registration Phase 3 study, known as SYNERGY, evaluating custirsen in patients with advanced prostate cancer. The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC)....

MARINA DEL REY, Calif., Sept. 7, 2012 /PRNewswire/ -- Prostate Oncology Specialists, Inc. is pleased to announce that its Medical Director, Mark Scholz, MD and Research Director, Richard Lam, MD will speak at the annual Prostate Cancer Research Institute's (PCRI) 2012 Conference being held in Los Angeles, CA on September 8-9, 2012. (Photo: http://photos.prnewswire.com/prnh/20101027/SF89964) (Photo: http://photos.prnewswire.com/prnh/20110816/SF53280) Dr. Lam will present two topics...